NASDAQ: ANIPAni Pharmaceuticals Inc Stock
$65.43-0.71 (-1.07%)
Updated Apr 24, 2024
ANIP Price
$65.43
Fair Value Price
-$52.80
Market Cap
$1.38B
52 Week Low
$36.99
52 Week High
$70.81
P/E
76.08x
P/B
3.19x
P/S
2.06x
PEG
0.83x
Dividend Yield
N/A
Revenue
$486.82M
Earnings
$18.78M
Gross Margin
62.7%
Operating Margin
9.62%
Profit Margin
3.5%
Debt to Equity
1.03
Operating Cash Flow
$119M
Beta
1.06
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ANIP Overview
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ANIP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANIP ($65.43) is overvalued by 223.93% relative to our estimate of its Fair Value price of -$52.80 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ANIP ($65.43) is not significantly undervalued (223.93%) relative to our estimate of its Fair Value price of -$52.80 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ANIP ($65.43) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ANIP due diligence checks available for Premium users.
Be the first to know about important ANIP news, forecast changes, insider trades & much more!
ANIP News
Valuation
ANIP fair value
Fair Value of ANIP stock based on Discounted Cash Flow (DCF)
Price
$65.43
Fair Value
-$52.80
Undervalued by
223.93%
ANIP ($65.43) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ANIP ($65.43) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ANIP ($65.43) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ANIP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
76.08x
Industry
47.66x
Market
41.27x
ANIP is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ANIP is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ANIP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.19x
Industry
2.06x
ANIP is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANIP price to earnings growth (PEG)
For valuing profitable companies with growth potential
ANIP is good value based... subscribe to Premium to read more.
PEG Value Valuation
ANIP's financial health
Profit margin
Revenue
$131.7M
Net Income
$1.2M
Profit Margin
0.6%
ANIP's Earnings (EBIT) of $46.81M... subscribe to Premium to read more.
Interest Coverage Financials
ANIP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$904.4M
Liabilities
$446.8M
Debt to equity
1.03
ANIP's short-term assets ($519.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANIP's short-term assets ($519.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANIP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ANIP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$44.7M
Investing
-$4.8M
Financing
-$11.9M
ANIP's operating cash flow ($118.96M)... subscribe to Premium to read more.
Debt Coverage Financials
ANIP vs Pharmaceutical Stocks
Ani Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.